In Covid-19, variations in fasting blood glucose are considered a distinct risk element for a
bad prognosis and outcome in Covid-19 patients. Tirazepatide (TZT), a dual glucagon-like …

The ongoing pandemic of COVID‐19 is intrinsically a systemic inflammatory disorder; hence,
those patients suffering an underlying chronic inflammatory disease such as diabetes …

Patients with diabetes have been reported to have enhanced susceptibility to severe or fatal
COVID-19 infections, including a high risk of being admitted to intensive care units with …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a
pandemic disease (COVID-19) that has spread globally causing more than 30,000 deaths …

Emerging data are linking coronavirus disease 2019 (COVID‐19) with an increased risk of
developing new‐onset diabetes. The gut has been so far out of the frame of the discussion …

Inflammation is implicated in the development and severity of the coronavirus disease 2019
(COVID-19), as well as in the pathophysiology of diabetes. Diabetes, especially when …

The growing amount of evidence suggests the existence of a bidirectional relation between
coronavirus disease 2019 (COVID-19) and type 2 diabetes mellitus (T2DM), as these two …

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has rapidly evolved into a global pandemic. The …

Introduction Understanding the pathogenesis and risk factors to control the coronavirus
disease 2019 (COVID-19) is necessary. Due to the importance of the inflammatory pathways …

Patients with SARS-CoV-2 infections experience lymphopenia and inflammatory cytokine
storms in the severe stage of the disease, leading to multi-organ damage. The exact pattern …